Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON37118
NL-OMON37118CompletedNot Applicable

A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of Radiolabeled [14C] R924548 Following Single Oral Dose Administration in Healthy Male Subjects - R548 ADME study

Rigel Pharmaceuticals, Inc0 sites6 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
6
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •Healthy male volunteers
  • •18-55 years of age
  • •BMI 18.0-31.0 kg/m2

Exclusion Criteria

  • •Suffering from: hepatitis B, cancer or HIV/AIDS.
  • •Participation in another drug study within 3 months before the start of this study.
  • •Blood donation within 3 months from the start of this study or in case you have donated more than 1.5 liters of blood in the 10 months before the start of this study.

Investigators

Similar Trials

Completed
Not Applicable
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of 14C-PTC299 Following Multiple Oral Dose Administrations in Healthy VolunteersAcute Leukemia
NL-OMON50826PTC Therapeutics, Inc.7
Completed
Not Applicable
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of PTC857 Following Oral Administration of a Single Dose of 14C-PTC857 at Steady-State Conditions in Healthy Male Volunteers.
NL-OMON51552PTC Therapeutics, Inc.8
Completed
Not Applicable
A Phase 1 study to investigate the absorption, metabolism and excretion of 14C-Orteronel (TAK-700) following a single oral administration in healthy subjects10036958Prostate cancer
NL-OMON36117Millenium Pharmaceuticals6
Completed
Not Applicable
A phase 1 study to investigate the absorption, metabolism and excretion of [14C] AT1001 (migalastat hydrochloride) following a single oral administration in healthy volunteers.
NL-OMON35820Amicus Therapeutics, Inc.6
Completed
Phase 1
Mass Balance Study of [14C]-S-600918 Oral Suspension in Healthy Male SubjectsHealthy subjects
JPRN-jRCT1080225285Shionogi B.V.6
A Phase I Study to Investigate the... | Clinical Trial